Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for China SXT Pharmaceuticals (SXTC) over the last 7 years, with Mar 2025 value amounting to $21.7 million.

  • China SXT Pharmaceuticals' Liabilities and Shareholders Equity fell 14.98% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.1 million, marking a year-over-year increase of 3.94%. This contributed to the annual value of $21.7 million for FY2025, which is 6.33% down from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Liabilities and Shareholders Equity of $21.7 million as of FY2025, which was down 6.33% from $23.1 million recorded in FY2024.
  • China SXT Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $34.5 million during FY2021, with a 5-year trough of $21.7 million in FY2025.
  • For the 3-year period, China SXT Pharmaceuticals' Liabilities and Shareholders Equity averaged around $24.8 million, with its median value being $23.1 million (2024).
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Liabilities and Shareholders Equity skyrocketed by 59.19% in 2021, and later declined by 21.75% in 2024.
  • Yearly analysis of 5 years shows China SXT Pharmaceuticals' Liabilities and Shareholders Equity stood at $34.5 million in 2021, then decreased by 2.90% to $33.5 million in 2022, then decreased by 11.90% to $29.6 million in 2023, then decreased by 21.75% to $23.1 million in 2024, then decreased by 6.33% to $21.7 million in 2025.